# Yehuda Handelsman Transcript: LDL targets (mainly for T2), statins, SGLT2 and PSCK9

**URL:** <https://forum.fudiabetes.org/t/yehuda-handelsman-transcript-ldl-targets-mainly-for-t2-statins-sglt2-and-psck9/3864>\
**Category:** Medicines\
**Created:** [April 8, 2018, 4:49pm UTC](https://forum.fudiabetes.org/t/yehuda-handelsman-transcript-ldl-targets-mainly-for-t2-statins-sglt2-and-psck9/3864 "2018-04-08T16:49:20Z")\
**Posts on this page:** 4\
**Page:** 1

<div class="post-metadata">

**Author:** ![bkh](https://avatars.discourse-cdn.com/v4/letter/b/da6949/32.png) [@bkh](https://forum.fudiabetes.org/u/bkh)\
**Post date:** [April 8, 2018, 4:49pm UTC](https://forum.fudiabetes.org/t/yehuda-handelsman-transcript-ldl-targets-mainly-for-t2-statins-sglt2-and-psck9/3864/1 "2018-04-08T16:49:20Z")

</div>

I came across a transcript of an interview with Yehuda Handelsman, former President of American College of Endocrinology. It is evident that he is not a native speaker of English, but I found the transcript to be well worth reading. [http://www.diabetesincontrol.com/yehuda-handelsman-transcript/](http://www.diabetesincontrol.com/yehuda-handelsman-transcript/)

He comes across as sensible and well-versed in the current research results concerning LDL targets. It turns out that they’ve introduced a new category of “extreme risk” for which the LDL target should be lowered to 55 because the research shows this gets a significant improvement in outcomes and it can be achieved without excessive side-effects via some of the newest medicines. He also touches on A1C targets and how quickly to get there, the utility of CGM for T2, and the promise of closed-loop systems.

---

<div class="post-metadata">

**Author:** ![Sam](https://yyz2.discourse-cdn.com/flex030/user_avatar/forum.fudiabetes.org/sam/32/10595_2.png) [@Sam](https://forum.fudiabetes.org/u/Sam)\
**Post date:** [April 8, 2018, 11:42pm UTC](https://forum.fudiabetes.org/t/yehuda-handelsman-transcript-ldl-targets-mainly-for-t2-statins-sglt2-and-psck9/3864/2 "2018-04-08T23:42:42Z")

</div>

This is interesting… they really are pushing for low LDL levels… I think I need to pursue this more with my doc…

---

<div class="post-metadata">

**Author:** ![docslotnick](https://yyz2.discourse-cdn.com/flex030/user_avatar/forum.fudiabetes.org/docslotnick/32/75_2.png) [@docslotnick](https://forum.fudiabetes.org/u/docslotnick)\
**Post date:** [April 8, 2018, 11:48pm UTC](https://forum.fudiabetes.org/t/yehuda-handelsman-transcript-ldl-targets-mainly-for-t2-statins-sglt2-and-psck9/3864/3 "2018-04-08T23:48:41Z")

</div>

My ldl levels have traditionally been around 70, but I just had a minor stroke. I wonder if lowering it to 50 would be of benefit. A good question to ask my docs on Thursday.

---

<div class="post-metadata">

**Author:** ![Sam](https://yyz2.discourse-cdn.com/flex030/user_avatar/forum.fudiabetes.org/sam/32/10595_2.png) [@Sam](https://forum.fudiabetes.org/u/Sam)\
**Post date:** [April 9, 2018, 12:15am UTC](https://forum.fudiabetes.org/t/yehuda-handelsman-transcript-ldl-targets-mainly-for-t2-statins-sglt2-and-psck9/3864/4 "2018-04-09T00:15:43Z")

</div>

Mine are nowhere near that low… my last lab showed an LDL of 122 but my doc said he wasn’t worried about it
